Design Therapeutics
DSGN
83 hedge funds and large institutions have $413M invested in Design Therapeutics in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 14 closing their positions.
371% more call options, than puts
Call options by funds: $5.82M | Put options by funds: $1.24M
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
5% more funds holding
Funds holding: 79 → 83 (+4)
2% less ownership
Funds ownership: 74.2% → 72.2% (-2%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less capital invested
Capital invested by funds: $692M → $413M (-$280M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$28.8M |
| 2 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$12.2M |
| 3 |
Millennium Management
New York
|
+$5.09M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.1M |
| 5 |
Rafferty Asset Management
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$25.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$22.1M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$10.1M |
| 4 |
Goldman Sachs
New York
|
-$9.75M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$4.69M |
DSGN Hedge Fund Activity: Q4 2022 in Review
83 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q4 2022, worth a combined $413M — down 40% from $692M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DSGN positions and 14 closed out — a net gain of 5 holders — while 29 added to existing stakes and 23 trimmed.
The largest buyer was State Street, adding an estimated $28.8M. The largest seller was Janus Henderson Group, cutting an estimated $25.8M.
- 83 institutional investors held Design Therapeutics (DSGN) as of Q4 2022, up from 79 in Q3 2022.
- Funds reported $413M of Design Therapeutics stock for Q4 2022, down 40% quarter-over-quarter.
- 19 funds opened new Design Therapeutics positions in Q4 2022 and 14 closed out, a net change of +5 holders.
- The largest Design Therapeutics buyer in Q4 2022 was State Street, an estimated $28.8M added.
- The largest Design Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $25.8M sold.
Based on aggregated 13F filings for Q4 2022.